Abstract. The MLL-AF9 oncogene originates from the translocation t(9;11)(p22;q23), which is mainly associated with monocytic acute myeloid leukaemia (AML-M5; FABclassification). In AML-M5 THP-1 cells carrying t(9;11) (p22;q23) and expressing MLL-AF9, we previously showed that MLL-AF9 expression is down-regulated during monocytemacrophage maturation. We have subsequently observed that in a 'rapid-growing' variant of the THP-1 cell line (THP-1-R) MLL-AF9 down-regulation does not occur. MLL fusion proteins (including MLL-AF9) deregulate MYC transactivation activity, and both presence and absence of MYC downregulation have been reported during monocyte-macrophage maturation in THP-1 cells. In the present study, we analyze the expression patterns of MLL-AF9, MLL wild-type and MYC after induction of monocyte-macrophage terminal differentiation in the AML-M5 cell lines, THP-1, THP-1-R, Mono-Mac-6 (MM6) and MOLM-13, all of which carry t(9;11)(p22;q23) and express MLL-AF9. RT-PCR analysis indicated that down-regulation of MLL-AF9, MLL or MYC is not necessary to abolish malignant phenotypes by induction of terminal monocyte-macrophage differentiation in leukaemic cells carrying t(9;11)(p22;q23).
Introduction
The MLL-AF9 oncogene (1, 2) originates from the translocation t(9;11)(p22;q23), which is mainly associated with monocytic acute myeloid leukaemia (AML-M5) (3) . We recently showed that MLL-AF9 expression is down-regulated during monocytemacrophage maturation induced by ATRA (all-trans-retinoicacid) or PMA/TPA (phorbol-12-myristate-13-acetate) in AML-M5 THP-1 cells (4) carrying t(9;11)(p22;q23) and expressing MLL-AF9 (5) . Since then, we have been surprised to observe that in THP-1 cells that have already undergone some months of continuous culture, PMA-or ATRA-induced differentiation is not accompanied by MLL-AF9 down-regulation. Intriguingly, conflicting reports exist on the presence (6) or absence (7) of MYC down-regulation in THP-1 cells after PMA-or ATRA-induced differentiation. The MYC and MLL wild-type proto-oncogenes are both essential for normal myeloid proliferation and development (8, 9) . Naturally occurring MLL fusion proteins, including MLL-AF9, are potent transcriptional co-activators that induce a deregulation of MYC transcriptional factor and activate the transcription of promoters containing MYC E boxes (10; Galoian K, et al, Blood: abs. 457, 2000) . The aim of the present study was to clarify the pattern of MLL-AF9, MLL and MYC expression after induction of monocyte-macrophage terminal differentiation in THP-1, MM6 and MOLM-13, all of which are AML-M5 cell lines carrying t(9;11)(p22;q23) and expressing MLL-AF9 (5, 11, 12) .
Materials and methods
Cell lines. MOLM-13 cells were a generous gift from Dr Yoshinobu Matsuo (Fujisaki-Cell-Center, Okayama, Japan). MOLM-13, THP-1, and MM6 cells were cultured as described (4, 12, 13) . Both types of THP-1 were differentiated with PMA (20 nM; Sigma, St. Louis, MO, USA) or ATRA (1 μM; Sigma), as previously reported (4). We have found that, like THP-1 cells, MOLM-13 cells are induced to stop proliferation and differentiate into mature macrophage-like cells within 24 h of treatment with PMA (20 nM). MOLM-13 cells had previously only been reported to differentiate to mature macrophage-like cells with interferon-Á, either alone or in combination with tumor necrosis factor-· (12) . As regards MM6 cells after PMA-treatment (80 nM), approximately 50% of cells became adherent and differentiated (13) . Accordingly, we have performed RT-PCR analysis only in adherent, nonproliferating MM6 cells, excluding cells still in suspension. For cell viability, cell aliquots were daily taken and counted in a haematocytometer; living cells were evaluated by trypanblue dye exclusion test.
Differentiation tests. Adherence: cells were considered to be adherent if they resisted vigorous shaking of the culture flask and washing by pipetting with normal growth medium. Phagocytosis and NBT (nitro blue tetrazolium reduction) tests: for phagocytosis, 1 μl of a 2.5% suspension of fluorescinatedlatex-beads (2 μm-diameter; Sigma) was added to control and treated cells (5x10 5 cells/ml). For NBT-reduction, control and treated cells (5x10 5 cells/ml) were resuspended in 200 μl PBS-(phosphate-buffered saline) containing 0.1% NBT and 100 ng/ml PMA. In both tests, after incubation (37˚C for 60 min), the cells were stained with May-Grunwald-Giemsa and viewed using fluorescence microscopy (for phagocytosis; cells were also PBS-washed to remove excess beads) or light microscopy (for NBT). The percentage of cells with ingested latex-beads or containing blue black granules was examined by scoring at least 300 cells. CD analysis: the FITC-conjugated monoclonal antibodies CD3-(clone-SK7), CD4-(clone-SK3), CD5-(clone-L17F12), CD7-(clone-4H9), CD10-(clone-HI10a), CD11b-(clone-D12), CD14-(clone-MPP9), CD15-(clone-MMA), CD19-(clone-4G7), CD33-(clone-P67.6), CD41a-(clone-HIP8) and CD42a-(clone-Beb1) were purchased from Becton-Dickinson. Control and treated cells (1x10 6 cells/ml in PBS) were incubated with antibody at room temperature for 15 min, PBS-washed and analysed using a FACScalibur flow-cytometer (Becton-Dickinson).
RT-PCR analysis. Total RNA was isolated using the 'RNeasyMini-Kit' (Qiagen, Santa Clarita, CA, USA), according to the manufacturer's instructions. Reverse transcription (RT) for a total volume of 20 μl was performed using a Super-Script ™ First-Strand Synthesis Kit (Gibco-BRL, Basel, Switzerland) according to the manufacturer's instructions. Standard polymerase chain reactions (PCRs) were performed using the primers listed in Table I . PCR conditions for MLL-AF9 amplification from MM6 cells were 4 cycles of 94˚C for 30 sec, 55˚C for 5 min and 68˚C for 10 min, followed by 35 cycles of 94˚C for 30 sec, 55˚C for 30 sec and 72˚C for 1 min, and finally one cycle of 72˚C for 6 min. PCRs were assayed on 2% agarose gel and stained with ethidium bromide (0.5 μg/ml). We recorded one MLL-AF9 amplification product in THP-1 cells (4), two in MM6 cells (11) , and two in MOLM-13 cells (14) . In all the cell lines examined, the housekeeping gene, ß-2M (ß-2 microglobulin), was constantly expressed at the same level. All experiments were repeated three times with similar results.
Results
As we have recently shown that MLL-AF9 expression is downregulated during monocyte-macrophage maturation in THP-1 cells (4), we have been surprised to observe that, in THP-1 cells that have already undergone some months of continuous culture, PMA-or ATRA-induced differentiation is not accompanied by MLL-AF9 down-regulation. As long-term in vitro culturing can modify cells' original characteristics, we first compared phenotypic features (proliferation rate, morphology, adherence, phagocytosis, NBT reduction, and expression of surface antigens) of the THP-1 cells continuously cultured for over 3 months with those of cells newly thawed from liquid nitrogen. The only detected difference regarded proliferation rate, which was increased in the continuously cultivated cells (Fig. 1, Table II ). This finding is consistent with a report that the original type of THP-1 cells [termed THP-1-O ('original')] and a THP-1 type continuously cultured after establishment [termed THP-1-R ('rapid')] retained the same phenotypic characteristics, except that THP-1-R cells showed a more rapid growth (15) . After treatment with PMA or ATRA, MLL-AF9 expression remained present in our differentiated Table I . Oligonucleotide primers for PCR amplification.
CTCCGGTCAATAAGCAGGAGAATG TCGGCTGCCTCCTCTATTTACAG 320 and 434 MLL-AF9 (MOLM-13) GAATCAGGTCCAGAGCAGAG  TCGGCTGCCTCCTCTATTTACAG  525 and 411  MLL  GAATCAGGTCCAGAGCAGAG  CTGAGGATGTTCAAAGTGCC  137  MYC  ACGAGGAGGAGAACTTCTACCAG  TTCACCATGTCTCCTCCCAGCAG  259  ß2M CCTTGAGGCTATCCAGCGTA TGGAGCAACCTGCTGCTCAGATA 522 THP-1-R cells until 72 h, whereas in THP-1-O cells no MLL-AF9 expression was detected after either treatment (Fig. 2) .
Successively, we have examined MLL-AF9 expression in MOLM-13 and MM6, two other AML-M5 cell lines carrying t(9;11)(p22;q23) (11, 12) . In PMA-differentiated cells, MLL-AF9 down-regulation was observed with MOLM-13 but not with MM6 cells, thus paralleling the results obtained with, respectively, THP-1-O and THP-1-R populations (Fig. 2) . We have also monitored the MLL wild-type expression pattern, which resulted in being similar to the MLL-AF9 expression pattern in all the cell lines tested (Fig. 2) .
The MYC expression pattern in undifferentiated/ differentiated THP-1, MM6, and MOLM-13 cells is shown in Fig. 2 . Interestingly, MYC expression was down-regulated in PMA-or ATRA-differentiated THP-1-O cells, but not in PMA-or ATRA-differentiated THP-1-R cells. This observation could explain previous conflicting reports describing the presence (6) or the absence (7) of MYC down-regulation in PMA-or ATRA-differentiated THP-1 cells. In these reports, culture and growth features were not characterized. We also found that MYC expression was not down-regulated in PMAdifferentiated MOLM-13 or MM6 cells. ONCOLOGY REPORTS 15: 207-211, 2006 Table II. Comparison of phenotypic characteristics between THP-1-O ('original' type) and THP-1-R cells ('rapid-growing' type). 
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Phenotypic characteristics of (A) untreated cells and (B) PMA-or ATRA-treated cells are shown. Values represent means ± s.d. of three separate experiments. CD4 and CD7 are ALL-T diagnostic markers, but they are also expressed in the myeloid lineage; MKE, megakaryocytic-erythrocytic.
Discussion
The data reported in this study support the hypothesis that MLL-AF9 oncogene expression does not affect the monocytemacrophage terminal differentiation process. In THP-1-O cells MLL-AF9 expression was down-regulated upon monocytemacrophage maturation induction (4) . However, in THP-1-R, this down-regulation did not occur (Fig. 2) , indicating that MLL-AF9 expression down-regulation was not obligatory for the induction and maintenance of a state of terminal monocytemacrophage differentiation of THP-1 cells. This result did not seem to be restricted to THP-1 cells. Indeed, MLL-AF9 down-regulation was observed with MOLM-13 but not with differentiated MM6 cells (Fig. 2) . Moreover, the terminal monocyte-macrophage differentiation induced by 1·,25-dihydroxyvitamin D3 in IMS-M1 AML-M5 cells, a line which also express MLL-AF9, does not require MLL-AF9 downregulation (Nagamura F, et al, Blood: abs. 587, 1995). In the light of these observations, MLL-AF9 down-regulation does not seem to be necessary for the induction of monocytemacrophage terminal differentiation in AML-M5 cells carrying t(9;11)(p22;q23). We have also assessed the MYC expression pattern and the findings indicated that down-regulation of MYC expression is also not required for the induction of monocytemacrophage terminal differentiation in AML-M5 cells carrying t(9;11)(p22;q23).
It has been reported that MLL-AF9 expression initially induces non-malignant expansion of myeloid precursors (2), with any perturbation of cellular differentiation being partial and largely reversible (16) . Moreover, MLL-AF9-targeted down-regulation reduces THP-1 cell growth (4,17) without affecting terminal differentiation (4) . MLL oncoproteins (including MLL-AF9) can deregulate MYC transactivation activity (10) , and expression of MYC maintains myeloid proliferation without, per se, controlling myeloid differentiation (18, 19) . Moreover, in the leukaemic K-562 cell line treated with PMA, MYC expression is down-regulated, but its ectopic overexpression does not inhibit monocyte-macrophage differentiation (20) .
These observations can be interpreted as evidence that MLL-AF9 expression can cause elevated myeloproliferation by a mechanism that involves MYC without affecting terminal differentiation processes. Induction of terminal differentiation usually leads to down-regulation of the genes governing cell division, thereby interrupting proliferation. The data from the present study indicate that leukemic cells carrying t(9;11) (p22;q23) do not require down-regulation of the MLL-AF9, MLL and MYC genes (involved in myeloid proliferation) to abolish the malignant phenotype by induction of terminal monocyte-macrophage differentiation.
While the down-regulation of the expression of the MLL-AF9, MLL and MYC genes is not necessary for monocytemacrophage maturation, further studies will be needed to determine if the block of myelo-monocytic differentiation, observed in leukemic cells expressing MLL-AF9, involves the suppression or the functional inhibition of the corresponding protein products. (12) , and two in MOLM-13 cells (23). In all the cell lines examined, the housekeeping gene, ß-2M (ß-2 microglobulin), was constantly expressed at the same level. All the experiments were repeated three times with similar results.
